Evotec AG reported double-digit increases in revenue for its drug discovery and service businesses for the 2018 first-half year, driven by new business from Aptuit, its recently acquired contract research unit. Revenue for the year is expected to grow by more than 30%.
Group revenue was €173.8 million for the first half, up by 67%. Drug discovery revenue was €32 million, up by 52%, while revenue from services to pharmaceutical partners was €163.3 million, up by 61%. There was an overlap of €21.5 million between the two units.